发明名称 |
FORMULATIONS OF 5-FLUOROCYTOSINE AND USES THEREOF |
摘要 |
The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine. |
申请公布号 |
US2016235751(A1) |
申请公布日期 |
2016.08.18 |
申请号 |
US201615136056 |
申请日期 |
2016.04.22 |
申请人 |
Tocagen Inc. |
发明人 |
Gruber Harry E.;Jolly Douglas J.;Olmstead Kay |
分类号 |
A61K31/513;A61K38/50;A61K9/20;A61K9/00 |
主分类号 |
A61K31/513 |
代理机构 |
|
代理人 |
|
主权项 |
1. A gastro-retentive oral pharmaceutical composition comprising 5-fluorocytosine (5-FC), wherein the pharmaceutical composition is a monolithic solid tablet form comprising at least one hydrophilic matrix forming polymer of about 5 to 40 weight percent, hydroxymethyl cellulose (HPC) and microcrystalline cellulose (MCC) of about 5 to 30 weight percent, dicalcium phosphate of about 11 weight percent, magnesium stearate and opadry white and releases 5-FC into the upper gastrointestinal tract of a subject over a sustained period of time. |
地址 |
San Diego CA US |